JP6770946B2 - ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤 - Google Patents

２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤 Download PDF

Info

Publication number
JP6770946B2
JP6770946B2 JP2017504062A JP2017504062A JP6770946B2 JP 6770946 B2 JP6770946 B2 JP 6770946B2 JP 2017504062 A JP2017504062 A JP 2017504062A JP 2017504062 A JP2017504062 A JP 2017504062A JP 6770946 B2 JP6770946 B2 JP 6770946B2
Authority
JP
Japan
Prior art keywords
weight
cancer
triazine
fluoro
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521469A (ja
JP2017521469A5 (enExample
Inventor
ゴンサルヴェス，エリザベート
タウフマン，クリスティン
イェン，シャウ−フォン
ヴィッパグンタ，スーダ
ゾン，ジーシン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6770946(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017521469A publication Critical patent/JP2017521469A/ja
Publication of JP2017521469A5 publication Critical patent/JP2017521469A5/ja
Application granted granted Critical
Publication of JP6770946B2 publication Critical patent/JP6770946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017504062A 2014-07-25 2015-07-22 ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤 Active JP6770946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
US62/028,865 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020058164A Division JP7002587B2 (ja) 2014-07-25 2020-03-27 ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤

Publications (3)

Publication Number Publication Date
JP2017521469A JP2017521469A (ja) 2017-08-03
JP2017521469A5 JP2017521469A5 (enExample) 2018-08-30
JP6770946B2 true JP6770946B2 (ja) 2020-10-21

Family

ID=53762251

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504062A Active JP6770946B2 (ja) 2014-07-25 2015-07-22 ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤
JP2020058164A Active JP7002587B2 (ja) 2014-07-25 2020-03-27 ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤
JP2021211526A Pending JP2022046659A (ja) 2014-07-25 2021-12-24 ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020058164A Active JP7002587B2 (ja) 2014-07-25 2020-03-27 ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤
JP2021211526A Pending JP2022046659A (ja) 2014-07-25 2021-12-24 ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3172209B1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR20230136693A (enExample)
CN (2) CN115364061A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA202191301A1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG11201700147SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TWI724993B (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
BR112019002007B1 (pt) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
BR112022007744A2 (pt) * 2019-10-24 2022-07-19 Hanmi Pharm Ind Co Ltd Preparação farmacêutica compreendendo um derivado de amida inibidor do crescimento de células câncer e produto farmacêutico que a contem
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762B (zh) * 2021-02-03 2026-03-06 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN120112284A (zh) 2022-08-19 2025-06-06 米拉蒂治疗股份有限公司 阿达格拉西布固体药物组合物
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2615063A1 (en) 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
SI2538925T1 (sl) 2010-02-25 2016-04-29 Bristol-Myers Squibb Company Apiksaban formulacije
PE20130216A1 (es) * 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
EP2590631B1 (en) * 2010-07-06 2016-10-26 Janssen Pharmaceutica NV Formulation for co-therapy treatment of diabetes
WO2014028566A1 (en) 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Also Published As

Publication number Publication date
US20210113569A1 (en) 2021-04-22
ECSP17011672A (es) 2018-03-31
AR101286A1 (es) 2016-12-07
EA201790259A1 (ru) 2017-06-30
CN115364061A (zh) 2022-11-22
EP3172209B1 (en) 2020-12-02
US12208101B2 (en) 2025-01-28
AU2020200912A1 (en) 2020-02-27
BR112017000953A2 (pt) 2017-11-14
HUS2200054I1 (hu) 2023-01-28
MX2021000595A (es) 2021-04-13
JO3618B1 (ar) 2020-08-27
AU2021202500A1 (en) 2021-05-20
JP2017521469A (ja) 2017-08-03
TWI724993B (zh) 2021-04-21
FR22C1058I2 (fr) 2023-11-17
CL2017000180A1 (es) 2017-09-15
JP2022046659A (ja) 2022-03-23
NZ728089A (en) 2024-01-26
US20250339440A1 (en) 2025-11-06
SI3172209T1 (sl) 2021-03-31
PH12017500121A1 (en) 2017-05-29
HUE053346T2 (hu) 2021-06-28
MX379279B (es) 2025-03-11
US20170231997A1 (en) 2017-08-17
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
CA2954840A1 (en) 2016-01-28
EP3172209A1 (en) 2017-05-31
JP7002587B2 (ja) 2022-01-20
FR22C1058I1 (fr) 2023-01-06
DK3172209T3 (da) 2021-02-22
TW201613595A (en) 2016-04-16
PT3172209T (pt) 2021-02-11
EP3848376A1 (en) 2021-07-14
KR20230136693A (ko) 2023-09-26
AU2018207947A1 (en) 2018-08-09
NL301208I2 (nl) 2025-03-20
IL250166A0 (en) 2017-03-30
MX2017001177A (es) 2017-05-01
US10085993B2 (en) 2018-10-02
JP2020114852A (ja) 2020-07-30
US20220249498A1 (en) 2022-08-11
TW202200148A (zh) 2022-01-01
KR102581121B1 (ko) 2023-09-21
MY187276A (en) 2021-09-17
NO2022058I1 (no) 2022-12-16
EA039220B1 (ru) 2021-12-20
KR20170039211A (ko) 2017-04-10
SG10201900648SA (en) 2019-02-27
PL3172209T3 (pl) 2021-06-14
WO2016012963A1 (en) 2016-01-28
GT201700007A (es) 2018-12-18
EA202191301A1 (ru) 2021-11-30
ES2857523T3 (es) 2021-09-29
IL250166B (en) 2021-01-31
US10596178B2 (en) 2020-03-24
CO2017000586A2 (es) 2017-06-20
PE20170523A1 (es) 2017-05-17
SG11201700147SA (en) 2017-02-27
AU2015293539A1 (en) 2017-02-02
US20190015418A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
JP7002587B2 (ja) ２－フルオロ－ｎ－メチル－４－［７－（キノリン－６－イルメチル）イミダゾ［１，２－ｂ］［１，２，４］トリアジン－２－イル］ベンズアミドの錠剤
US20230339957A1 (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
EP1651233A2 (en) Pharmaceutical composition
HK40049437A (en) Tablet formulation of a c-met inhibitor
JP7370125B2 (ja) エルロチニブを有効成分とする医薬錠剤
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
HK1231863A1 (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
HK1231863B (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
EA050835B1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
JP7370124B2 (ja) エルロチニブを有効成分とする医薬錠剤
BR112017000953B1 (pt) Comprimido compreendendo 2-flúor-n-metil-4-[7-(quinolin6-il-metil) imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
JP6945377B2 (ja) エルロチニブを有効成分とする医薬錠剤及びその製造方法
EP2694039A1 (en) Solid preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200327

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200327

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200407

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200508

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200928

R150 Certificate of patent or registration of utility model

Ref document number: 6770946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250